Advertisement

Roflumilast ameliorates cognitive impairment in APP/PS1 mice via cAMP/CREB/BDNF signaling and anti-neuroinflammatory effects

  • Huancun Feng
  • Canmao Wang
  • Wei He
  • Xinjun Wu
  • Shujie Li
  • Zhenkun Zeng
  • Meidan Wei
  • Binghong HeEmail author
Original Article

Abstract

Phosphodiesterase type 4 (PDE4) inhibitors can prevent the breakdown of the second messenger cyclic adenosine monophosphate (cAMP) and improve cognitive performances in several animal models of cognition. However, the clinical development of PDE4 inhibitors has been seriously hampered by severe side effects, such as vomiting and nausea. In this study, we investigated the effect and mechanism of roflumilast, an FDA-approved PDE4 inhibitor for treatment of chronic obstructive pulmonary disease (COPD), on learning and memory abilities in the APP/PS1 mouse model of Alzheimer’s disease (AD). APP/PS1 transgenic mice received 3 intragastric doses of roflumilast (0.1, 0.2 and 0.4 mg/kg) daily for 3 weeks followed by behavioral tests. Chronic administration of roflumilast significantly improved the learning and memory abilities of APP/PS1 transgenic mice in the novel object recognition task, Morris water maze, and the step-down passive avoidance task. In addition, roflumilast increased the cAMP, phosphorylated cAMP response-element binding protein (p-CREB) and brain-derived neurotrophic factor (BDNF) levels, and reduced the nuclear translocation of nuclear factor-kappa B (NF-κB) p65, and proinflammatory cytokine (IL-6, TNF-a and IL-1β) levels in the hippocampus of APP/PS1 transgenic mice. In conclusion, these findings suggest that roflumilast can enhance cognitive function in APP/PS1 transgenic mice, which may be related to its stimulation of the cAMP/CREB/BDNF pathway and anti-neuroinflammatory effects.

Keywords

Roflumilast Phosphodiesterase-4 Alzheimer’s disease cAMP-response element binding protein (CREB) Neuroinflammation Cognition 

Notes

Acknowledgements

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Compliance with ethical standards

Conflicts of interest

The authors declare that there are no conflicts of interest.

References

  1. Akar F, Mutlu O, Celikyurt IK, Bektas E, Tanyeri MH, Ulak G, Tanyeri P, Erden F (2014) Effects of zaprinast and rolipram on olfactory and visual memory in the social transmission of food preference and novel object recognition tests in mice. Drug Target Insights 8:23–29CrossRefGoogle Scholar
  2. Akar F, Mutlu O, Celikyurt IK, Ulak G, Erden F, Bektas E, Tanyeri P (2015) Effects of rolipram and zaprinast on learning and memory in the Morris water maze and radial arm maze tests in naive mice. Drug Res (Stuttg) 65:86–90Google Scholar
  3. Bambah-Mukku D, Travaglia A, Chen DY, Pollonini G, Alberini CM (2014) A positive autoregulatory BDNF feedback loop via C/EBPbeta mediates hippocampal memory consolidation. J Neurosci 34:12547–12559CrossRefGoogle Scholar
  4. Barage SH, Sonawane KD (2015) Amyloid cascade hypothesis: pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides 52:1–18CrossRefGoogle Scholar
  5. Bolos M, Perea JR, Avila J (2017) Alzheimer's disease as an inflammatory disease. Biomol Concepts 8:37–43CrossRefGoogle Scholar
  6. Bruce-Keller AJ, Gupta S, Knight AG, Beckett TL, McMullen JM, Davis PR, Murphy MP, van Eldik LJ, St Clair D, Keller JN (2011) Cognitive impairment in humanized APPxPS1 mice is linked to Abeta (1-42) and NOX activation. Neurobiol Dis 44:317–326CrossRefGoogle Scholar
  7. Chong J, Leung B, Poole P (2017) Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 9:CD002309PubMedGoogle Scholar
  8. Daniilidou M, Koutroumani M, Tsolaki M (2011) Epigenetic mechanisms in Alzheimer's disease. Curr Med Chem 18:1751–1756CrossRefGoogle Scholar
  9. Dansokho C, Heneka MT (2017) Neuroinflammatory responses in Alzheimer's disease. J Neural Transm (Vienna) 125:771–779CrossRefGoogle Scholar
  10. Dewapriya P, Li YX, Himaya SW, Pangestuti R, Kim SK (2013) Neoechinulin a suppresses amyloid-beta oligomer-induced microglia activation and thereby protects PC-12 cells from inflammation-mediated toxicity. Neurotoxicology 35:30–40CrossRefGoogle Scholar
  11. Dworkin S, Mantamadiotis T (2010) Targeting CREB signalling in neurogenesis. Expert Opin Ther Targets 14:869–879CrossRefGoogle Scholar
  12. Garcia-Osta A, Cuadrado-Tejedor M, Garcia-Barroso C, Oyarzabal J, Franco R (2012) Phosphodiesterases as therapeutic targets for Alzheimer's disease. ACS Chem Neurosci 3:832–844CrossRefGoogle Scholar
  13. Gong B, Vitolo OV, Trinchese F, Liu S, Shelanski M, Arancio O (2004) Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment. J Clin Invest 114:1624–1634CrossRefGoogle Scholar
  14. Guo HB, Y F C, Wu JG et al (2015) Donepezil improves learning and memory deficits in APP/PS1 mice by inhibition of microglial activation. Neuroscience 290:530–542CrossRefGoogle Scholar
  15. Guo H, Cheng Y, Wang C, Wu J, Zou Z, Niu B, Yu H, Wang H, Xu J (2017) FFPM, a PDE4 inhibitor, reverses learning and memory deficits in APP/PS1 transgenic mice via cAMP/PKA/CREB signaling and anti-inflammatory effects. Neuropharmacology 116:260–269CrossRefGoogle Scholar
  16. Haraguchi S, Good RA, Day NK (1995) Immunosuppressive retroviral peptides: cAMP and cytokine patterns. Immunol Today 16:595–603CrossRefGoogle Scholar
  17. Jabaris SG, Sumathy H, Kumar RS et al (2015) Effects of rolipram and roflumilast, phosphodiesterase-4 inhibitors, on hypertension-induced defects in memory function in rats. Eur J Pharmacol 746:138–147CrossRefGoogle Scholar
  18. Jiang LI, Sternweis PC, Wang JE (2013) Zymosan activates protein kinase a via adenylyl cyclase VII to modulate innate immune responses during inflammation. Mol Immunol 54:14–22CrossRefGoogle Scholar
  19. Josselyn SA, Nguyen PV (2005) CREB, synapses and memory disorders: past progress and future challenges. Curr Drug Targets CNS Neurol Disord 4:481–497CrossRefGoogle Scholar
  20. Kandel ER (2012) The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol Brain 5:14CrossRefGoogle Scholar
  21. Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov 10:698–712CrossRefGoogle Scholar
  22. Lakics V, Karran EH, Boess FG (2010) Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 59:367–374CrossRefGoogle Scholar
  23. Liu M, Wei Y, Yang Y et al (2017) Effects and mechanism of Huannao Yicong decoction extract on the ethology of transgenic APP/PS1 mice. Evid Based Complement Alternat Med 2017:9502067PubMedPubMedCentralGoogle Scholar
  24. Lonze BE, Ginty DD (2002) Function and regulation of CREB family transcription factors in the nervous system. Neuron 35:605–623CrossRefGoogle Scholar
  25. Lopez-Gonzalez I, Schluter A, Aso E et al (2015) Neuroinflammatory signals in Alzheimer disease and APP/PS1 transgenic mice: correlations with plaques, tangles, and oligomeric species. J Neuropathol Exp Neurol 74:319–344CrossRefGoogle Scholar
  26. Luccarini I, Grossi C, Traini C, Fiorentini A, Ed Dami T, Casamenti F (2012) Abeta plaque-associated glial reaction as a determinant of apoptotic neuronal death and cortical gliogenesis: a study in APP mutant mice. Neurosci Lett 506:94–99CrossRefGoogle Scholar
  27. Nagakura A, Shitaka Y, Yarimizu J, Matsuoka N (2013) Characterization of cognitive deficits in a transgenic mouse model of Alzheimer's disease and effects of donepezil and memantine. Eur J Pharmacol 703:53–61CrossRefGoogle Scholar
  28. Pan XD, Chen XC, Zhu YG, Chen LM, Zhang J, Huang TW, Ye QY, Huang HP (2009) Tripchlorolide protects neuronal cells from microglia-mediated beta-amyloid neurotoxicity through inhibiting NF-kappaB and JNK signaling. Glia 57:1227–1238CrossRefGoogle Scholar
  29. Pinner NA, Hamilton LA, Hughes A (2012) Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Clin Ther 34:56–66CrossRefGoogle Scholar
  30. Poole RM, Ballantyne AD (2014) Apremilast: first global approval. Drugs 74:825–837CrossRefGoogle Scholar
  31. Press NJ, Banner KH (2009) PDE4 inhibitors - a review of the current field. Prog Med Chem 47:37–74CrossRefGoogle Scholar
  32. Puzzo D, Vitolo O, Trinchese F et al (2005) Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J Neurosci 25:6887–6897CrossRefGoogle Scholar
  33. Robichaud A, Savoie C, Stamatiou PB, Lachance N, Jolicoeur P, Rasori R, Chan CC (2002) Assessing the emetic potential of PDE4 inhibitors in rats. Br J Pharmacol 135:113–118CrossRefGoogle Scholar
  34. Rutten K, Prickaerts J, Blokland A (2006) Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 85:132–138CrossRefGoogle Scholar
  35. Rutten K, Lieben C, Smits L, Blokland A (2007) The PDE4 inhibitor rolipram reverses object memory impairment induced by acute tryptophan depletion in the rat. Psychopharmacology 192:275–282CrossRefGoogle Scholar
  36. Saura CA, Valero J (2011) The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev Neurosci 22:153–169CrossRefGoogle Scholar
  37. Scearce-Levie K (2011) Monitoring spatial learning and memory in Alzheimer's disease mouse models using the Morris water maze. Methods Mol Biol 670:191–205CrossRefGoogle Scholar
  38. Sierksma AS, van den Hove DL, Pfau F et al (2014) Improvement of spatial memory function in APPswe/PS1dE9 mice after chronic inhibition of phosphodiesterase type 4D. Neuropharmacology 77:120–130CrossRefGoogle Scholar
  39. Smith DL, Pozueta J, Gong B, Arancio O, Shelanski M (2009) Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc Natl Acad Sci U S A 106:16877–16882CrossRefGoogle Scholar
  40. Swerdlow RH (2012) Alzheimer's disease pathologic cascades: who comes first, what drives what. Neurotox Res 22:182–194CrossRefGoogle Scholar
  41. Van Duinen MA, Sambeth A, Heckman P et al (2018) Acute administration of roflumilast enhances immediate recall of verbal word memory in healthy young adults. Neuropharmacology 131:31–38CrossRefGoogle Scholar
  42. Vanmierlo T, Creemers P, Akkerman S, van Duinen M, Sambeth A, de Vry J, Uz T, Blokland A, Prickaerts J (2016) The PDE4 inhibitor roflumilast improves memory in rodents at non-emetic doses. Behav Brain Res 303:26–33CrossRefGoogle Scholar
  43. Veremeyko T, Yung A, Dukhinova M et al (2018) Cyclic AMP pathway suppress autoimmune neuroinflammation by inhibiting functions of encephalitogenic CD4 T cells and enhancing M2 macrophage polarization at the site of inflammation. Front Immunol 9:50CrossRefGoogle Scholar
  44. Wang C, Yang XM, Zhuo YY, Zhou H, Lin HB, Cheng YF, Xu JP, Zhang HT (2012) The phosphodiesterase-4 inhibitor rolipram reverses Abeta-induced cognitive impairment and neuroinflammatory and apoptotic responses in rats. Int J Neuropsychopharmacol 15:749–766CrossRefGoogle Scholar
  45. Wang G, Chen L, Pan X, Chen J, Wang L, Wang W, Cheng R, Wu F, Feng X, Yu Y, Zhang HT, O'Donnell JM, Xu Y (2016) The effect of resveratrol on beta amyloid-induced memory impairment involves inhibition of phosphodiesterase-4 related signaling. Oncotarget 7:17380–17392PubMedPubMedCentralGoogle Scholar
  46. Webster SJ, Bachstetter AD, Van Eldik LJ (2013) Comprehensive behavioral characterization of an APP/PS-1 double knock-in mouse model of Alzheimer's disease. Alzheimers Res Ther 5:28CrossRefGoogle Scholar
  47. Wengenack TM, Whelan S, Curran GL, Duff KE, Poduslo JF (2000) Quantitative histological analysis of amyloid deposition in Alzheimer's double transgenic mouse brain. Neuroscience 101:939–944CrossRefGoogle Scholar
  48. Wortmann M (2012) Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther 4:40PubMedPubMedCentralGoogle Scholar
  49. Yamamoto M, Gotz ME, Ozawa H et al (2000) Hippocampal level of neural specific adenylyl cyclase type I is decreased in Alzheimer's disease. Biochim Biophys Acta 1535:60–68CrossRefGoogle Scholar
  50. Yamamoto-Sasaki M, Ozawa H, Saito T, Rosler M, Riederer P (1999) Impaired phosphorylation of cyclic AMP response element binding protein in the hippocampus of dementia of the Alzheimer type. Brain Res 824:300–303CrossRefGoogle Scholar
  51. Yamashima T (2012) 'PUFA-GPR40-CREB signaling' hypothesis for the adult primate neurogenesis. Prog Lipid Res 51:221–231CrossRefGoogle Scholar
  52. Zemek F, Drtinova L, Nepovimova E et al (2014) Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine. Expert Opin Drug Saf 13:759–774PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Pharmacy, The Third Affiliated HospitalSouthern Medical UniversityGuangzhouChina
  2. 2.Department of PharmacyShenzhen University General HospitalShenzhenChina
  3. 3.Department of BiologyEast Carolina UniversityGreenvilleUSA

Personalised recommendations